menu
    • menu
    [{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"IAM-H1","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iambic Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Iambic Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"5","companyTruncated":"Iambic Therapeutics \/ Ascenta Capital"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IAM1363","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Iambic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Iambic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Iambic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"IAM1363","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iambic Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Iambic Therapeutics \/ Mubadala Capital","highestDevelopmentStatusID":"6","companyTruncated":"Iambic Therapeutics \/ Mubadala Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Iambic Therapeutics

    Menu

    Iambic Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Iambic Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Iambic Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAM1363,Trastuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Mubadala Capital

                            Deal Size : $150.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Iambic Closes $50M Series B Extension to Broaden AI-Discovered Oncology Programs

                            Details : The proceeds from the financing will be used to advance the IAM1363, a highly selective, brain-penetrant small molecule inhibitor, being evaluated for the treatment of HER2-mutated neoplasms.

                            Brand Name : IAM1363

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 18, 2024

                            Lead Product(s) : IAM1363,Trastuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Mubadala Capital

                            Deal Size : $150.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Iambic Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Iambic Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAM1363

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Iambic Therapeutics To Present Data for IAM1363 At AACR Annual Meeting

                            Details : IAM1363 inhibits both wild type and mutant HER2 forms, showing over 1000-fold selectivity against EGFR, being evaluated for HER2-driven cancers.

                            Brand Name : IAM1363

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 28, 2024

                            Lead Product(s) : IAM1363

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Iambic Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Iambic Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAM-H1

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Ascenta Capital

                            Deal Size : $100.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered...

                            Details : The financing will advance multiple candidates into clinical development, expand its pipeline with best-in-class and first-in-class potential, including IAM-H1, a Selective Brain-Penetrant HER2 Inhibitor, and IAM-C1, a Selective Dual CDK2/4 Inhibitor.

                            Brand Name : IAM-H1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 03, 2023

                            Lead Product(s) : IAM-H1

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Ascenta Capital

                            Deal Size : $100.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth